Silexion Therapeutics Announces Patient Dosed in Phase 2/3 Pancreatic Cancer Trial

What Happened

• On September 30, 2026, Silexion Therapeutics Corp (NASDAQ: SLXN) announced via press release that the first patient has been successfully dosed in its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer. The company furnished the press release as Exhibit 99.1 to a Form 8-K filed the same day (Item 7.01, Regulation FD Disclosure).

Key Details

• Filing date: September 30, 2026 (Form 8-K, Item 7.01).
• Program: SIL204, in a Phase 2/3 clinical trial targeting locally advanced pancreatic cancer.
• Milestone: First patient successfully dosed (press release titled “Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer”).
• Press release furnished as Exhibit 99.1 to the Form 8-K.

Why It Matters

• The dosing of the first patient is a concrete operational milestone in Silexion’s clinical development of SIL204 and advances the company’s clinical program toward later-stage data readouts. Investors often view first-patient-dosed events as indicators that a trial is underway and on schedule; the company’s public disclosure via Form 8-K makes the update material and timely for shareholders.